611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO, CA
Directors Elected at Structure Therapeutics Inc. Annual General Meeting
Reports First Quarter 2026 Financial Results and Recent Highlights
Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel
Topline ACCESS II and Supplementary Studies
Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
Material Agreement with Genentech for GLP-1 Receptor Agonists
Structure Therapeutics Announces Follow-On Public Offering of ADSs
Topline ACCESS Phase 2b Results
Q1
FY 2025
Q3
Q2
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities